behindthebid

Soliton $SOLY Will Likely Trail Down Until Next Catalyst

Short
NASDAQ:SOLY   None
Soliton reported highly anticipated results from its study on cellulite reduction on Monday, July 15th. In anticipation, the stock ran from $12 to $20, but on the day of, the stock closed down 15%.

Soliton is a small cap medical device company that has an acoustic shockwave technology for tattoo removal called Rapid Acoustic Pulse (RAP). The treatment works pretty well, needing only 2-3 visits to remove tattoos vs the standard of care (lasers) which take about 10 doctor visits. They have also put a lot of press out about the potential of using their device for cellulite.

It's worth nothing that this was their second cellulite trial. The company presented their first trial results using RAP to treat cellulite on May 11 at the National Aesthetics Conference. They also went on Yahoo Finance Video to talk about the results. The trial "succeeded" said management, however, the stock responded less than enthusiastically.

The Full Article Is At BehindTheBid.com (CLICK HERE)

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.